Search results for "bronchodilator agents"

showing 10 items of 104 documents

Adjustable maintenance dosing with budesonide/formoterol in a single inhaler provides effective asthma symptom control at a lower dose than fixed mai…

2004

Asthma guidelines suggest a stepwise approach to maintenance pharmacological treatment of persistent asthma until control is attained, and a 3 month review of the fixed maintenance dosing for step-up or step-down adjustment. This 12-week study compared the efficacy and safety of budesonide/formoterol in a single inhaler (Symbicort Turbuhaler 160/4.5 or 80/4.5 microg) given as adjustable maintenance or fixed maintenance dosing. Patients (n = 2358) were randomised to budesonide/formoterol fixed maintenance dosing (two inhalations bid) or adjustable maintenance dosing (two inhalation bid; stepping up to four inhalations bid if asthma worsened for a maximum of 14 days; stepping down to two inha…

AdultMalePulmonary and Respiratory MedicineBudesonidemedicine.drug_classDrug Administration ScheduleFormoterol FumarateBronchodilatormedicineHumansPharmacology (medical)DosingBudesonideathma; therapy; guidelinesAsthmaDose-Response Relationship DrugInhalationbusiness.industryNebulizers and VaporizersInhalerBiochemistry (medical)medicine.diseaseAsthmaBronchodilator Agentsrespiratory tract diseasesTreatment OutcomeBudesonide/formoterolEthanolaminesAnesthesiaDrug Therapy CombinationFemaleFormoterolbusinessmedicine.drugPulmonary Pharmacology & Therapeutics
researchProduct

Tiotropium Respimat® in asthma: a double-blind, randomised, dose-ranging study in adult patients with moderate asthma

2013

Tiotropium, a once-daily long-acting anticholinergic bronchodilator, when administered via Respimat® SoftMist™ inhaler (tiotropium Respimat®) significantly reduces the risk of severe exacerbations and improves lung function in patients with severe persistent asthma that is not fully controlled despite using inhaled corticosteroids (ICS) and long-acting β2-agonists. To further explore the dose–response curve in asthma, we investigated the efficacy and safety of three different doses of tiotropium Respimat® as add-on to ICS in symptomatic patients with moderate persistent asthma. In this randomised, double-blind, placebo-controlled, four-way crossover study, patients were randomised to tiotro…

AdultMalePulmonary and Respiratory MedicineRespimatmedicine.drug_classScopolamine DerivativesPlaceboFEV1/FVC ratioDouble-Blind MethodCholinergic antagonistsBronchodilatorAdministration InhalationmedicineHumansTiotropium BromideAsthmaCross-Over StudiesDose-Response Relationship Drugbusiness.industryResearchTiotropiumTiotropium bromideMiddle AgedBronchodilator agentsmedicine.diseaseDose-ranging studyCrossover studyAsthmaRespimatrespiratory tract diseasesClinical trialAnesthesiaFemalebusinessmedicine.drugFollow-Up StudiesRespiratory Research
researchProduct

Inhaled Corticosteroids and the Beneficial Effect of Deep Inspiration in Asthma

2005

Deep inspiration-induced bronchoprotection and bronchodilation are impaired in asthma. We evaluated the effect of inhaled glucocorticosteroids on these phenomena. Two groups of subjects with asthma, 9 with moderate/severe hyperresponsiveness to methacholine, and 12 with mild/borderline hyperresponsiveness to methacholine, received inhaled fluticasone (880 microg daily) for 12 weeks. Serial bronchoprovocations were performed at Weeks 0, 6, and 12. The impact of deep inspirations on the airway response to methacholine was evaluated on the basis of inspiratory vital capacity and FEV(1). Fluticasone produced a wide spectrum of changes in the beneficial effects of deep inspiration, but the mean …

AdultMalePulmonary and Respiratory MedicineRespiratory Therapymedicine.drug_classVital CapacityRespiratory physiologySettore MED/10 - Malattie Dell'Apparato RespiratorioCritical Care and Intensive Care MedicineSeverity of Illness IndexBronchial Provocation TestsBronchoconstrictor AgentsForced Expiratory VolumeIntensive careAdministration Inhalationlung inflation asthma treatmentBronchodilationmedicineHumansMethacholine ChlorideAgedFluticasoneAsthmaInhalationbusiness.industryMiddle Agedmedicine.diseaseAsthmaBronchodilator AgentsA. Asthma and Allergyrespiratory tract diseasesAndrostadienesInhalationAnesthesiaRespiratory MechanicsFluticasoneCorticosteroidFemaleMethacholineBronchial Hyperreactivitybusinessmedicine.drugAmerican Journal of Respiratory and Critical Care Medicine
researchProduct

Exhaled Nitric Oxide Measurement Is Not Useful for Predicting the Response to Inhaled Corticosteroids in Subjects With Chronic Cough

2009

Background Increased concentrations of exhaled nitric oxide (ENO) are identified predominantly in subjects with chronic cough due to conditions that habitually respond well to therapy with inhaled corticosteroids (ICSs). The aim of this study was to assess the usefulness of ENO in predicting the response to ICS therapy in subjects with chronic cough and to determine the relationship between either methacholine or adenosine 5′-monophosphate (AMP) responsiveness and the response to ICS therapy. Methods A total of 43 patients with chronic cough were studied. During the baseline period, ENO measurement, spirometry, and concentration-response studies with both methacholine and AMP were performed…

AdultMalePulmonary and Respiratory MedicineSpirometryAdolescentmedicine.drug_classNitric OxideCritical Care and Intensive Care MedicineSensitivity and SpecificityBronchial Provocation TestsFluticasone propionatePredictive Value of TestsAdministration InhalationmedicineHumansProspective StudiesMethacholine ChlorideAgedFluticasoneInhalationmedicine.diagnostic_testbusiness.industryMiddle AgedAdenosine MonophosphateBronchodilator AgentsAndrostadienesChronic coughCoughROC CurveSpirometryAnesthesiaChronic DiseaseExhaled nitric oxideFluticasoneCorticosteroidFemaleMethacholinemedicine.symptomCardiology and Cardiovascular Medicinebusinessmedicine.drugChest
researchProduct

Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: The BRIGHT study

2014

Summary Introduction QVA149 is a novel, inhaled, once-daily dual bronchodilator containing a fixed-dose combination of the long-acting β 2 -agonist indacaterol and the long-acting muscarinic antagonist glycopyrronium (NVA237), for the treatment of chronic obstructive pulmonary disease (COPD). This study evaluated the effects of QVA149 on exercise tolerance, hyperinflation, lung function and lung volumes versus placebo and tiotropium. Methods Patients with moderate-to-severe COPD were randomized to QVA149 110/50 μg, placebo or tiotropium 18 μg once daily in a blinded, 3-period crossover study for 3 weeks. The primary endpoint was exercise endurance time at Day 21 for QVA149 versus placebo. R…

AdultMalePulmonary and Respiratory Medicinemedicine.drug_classVital CapacityScopolamine DerivativesHyperinflationQuinolonesPlaceboDrug Administration SchedulePulmonary Disease Chronic ObstructiveFunctional residual capacityDouble-Blind MethodForced Expiratory VolumeBronchodilatormedicineClinical endpointHumansLung volumesTiotropium BromideExerciseAgedCOPDCross-Over StudiesExercise Tolerancebusiness.industryChronic obstructive pulmonary diseaseTiotropiumQVA149Middle Agedmedicine.diseaseGlycopyrrolateCrossover studyBronchodilator Agentsrespiratory tract diseasesDrug CombinationsTreatment OutcomeSpirometryAnesthesiaIndansIndacaterolFemaleLung Volume Measurementsbusinessmedicine.drugRespiratory Medicine
researchProduct

Prospective evaluation of current asthma control using ACQ and ACT compared with GINA criteria

2011

Background The goal of asthma treatment is to achieve and maintain current best control and reduce future risk of exacerbations and long-term morbidity. Objective To prospectively compare current asthma control as defined by ACQ (asthma control questionnaire) and ACT (asthma control test) criteria with the GINA (Global Initiative for Asthma) classification in treated patients in a real-life setting. Methods In 150 adult patients (48% male, age 46.3 ± 14.4 years., forced expiratory volume in 1 second [FEV 1 ], 2.3 ± 0.9 L or 78.5 ± 21.8% pred.), asthma control was evaluated using the GINA classification as the "true" and ACQ-7, ACQ-5, and ACT as "predictor" criteria. The relationship between…

AdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtySevere asthmaImmunologySensitivity and SpecificitySeverity of Illness IndexProspective evaluationPredictive Value of TestsForced Expiratory VolumeSurveys and QuestionnairesInternal medicineAsthma controlmedicineHumansImmunology and AllergyProspective StudiesAsthmaAdult patientsbusiness.industryMiddle Agedmedicine.diseasePredictive valueAsthmaBronchodilator Agentsrespiratory tract diseasesUncontrolled asthmaAsthma Control QuestionnairePhysical therapyFemalebusinessAnnals of Allergy, Asthma & Immunology
researchProduct

Influence of low temperature on bronchodilatation induced by terbutaline administered by metered dose or dry powder inhalers in asthmatics.

2000

Low temperatures may affect dose delivery efficacy and clinical effectiveness of medication aerosols. In this study we examine the effect of cold ambient temperature on the bronchodilatation produced by terbutaline delivered from a chlorofluorocarbon pressurized metered dose inhaler (pMDI) compared to a multi-dose dry powder inhaler (DPI). Fourteen stable asthmatics were studied on two consecutive days. On day 1, after measuring FEV1 at room temperature (22 degrees C), each patient was randomized to receive 500 microg of terbutaline delivered from pMDI or DPI stored for 24 h at 22 degrees C with FEV1 recorded 20 min post-dose; then, patients were placed in a chamber at -10 degrees C, and af…

AdultMalemedicine.drug_classTerbutalineCold storageBronchiBronchodilatorForced Expiratory VolumeAdministration InhalationmedicineTerbutalineHumansPharmacology (medical)PharmacologyDose-Response Relationship DrugCumulative doseChemistryInhalerAdrenergic beta-AgonistsMiddle AgedMetered-dose inhalerDry-powder inhalerAsthmaBronchodilator AgentsCold TemperatureBronchodilatationAnesthesiaFemalePowdersmedicine.drugFundamentalclinical pharmacology
researchProduct

The bronchodilation response to deep inspiration in asthma is dependent on airway distensibility and air trapping

2011

In healthy individuals, deep inspirations (DIs) have a potent bronchodilatory ability against methacholine (MCh)-induced bronchoconstriction. This is variably attenuated in asthma. We hypothesized that inability to bronchodilate with DIs is related to reduced airway distensibility. We examined the relationship between DI-induced bronchodilation and airway distensibility in 15 asthmatic individuals with a wide range of baseline lung function [forced expired volume in 1 s (FEV1) = 60–99% predicted]. After abstaining from DIs for 20 min, subjects received a single-dose MCh challenge and then asked to perform DIs. The effectiveness of DIs was assessed by the ability of the subjects to improve …

AdultMalemedicine.medical_specialtyAdolescentPhysiologymethacholine bronchoconstriction imagingSettore MED/10 - Malattie Dell'Apparato RespiratorioAir trappingBronchial Provocation TestsYoung AdultAirway resistancePhysiology (medical)Internal medicineBronchodilationmedicineHumansMethacholine ChlorideAsthmaInhalationbusiness.industryAirway ResistanceArticlesMiddle Agedrespiratory systemAirway obstructionmedicine.diseaseAsthmaBronchodilator Agentsrespiratory tract diseasesInhalationAnesthesiaCardiologyFemaleBronchoconstrictionMethacholinemedicine.symptombusinessmedicine.drug
researchProduct

Measurement of inflammatory mediators of eosinophils and lymphocytes in blood in acute asthma: serum levels of ECP influence the bronchodilator respo…

2002

The aim of this study was to assess the relevance of immunoinflammatory markers on the response to short acting β<sub>2</sub>-agonist in acute asthma exacerbation. Thus, we measured serum eosinophil cationic protein (ECP) levels and sIL-2R at acute exacerbation in 52 adult patients with atopic asthma, and assessed forced expiratory volume in 1 s (FEV<sub>1</sub>) before and after the administration of aerosolized salbutamol. After a cumulative dose of salbutamol causing a 10% improvement in FEV<sub>1</sub> from baseline [CD10, i.e. cumulative doses of salbutamol (800 µg) causing an improvement in FEV<sub>1</sub> from baseline to 10%] the patie…

AdultMalemedicine.medical_specialtyExacerbationAdolescentmedicine.drug_classImmunologyStatistics NonparametricRibonucleasesInternal medicineBronchodilatorForced Expiratory VolumemedicineImmunology and AllergyHumansAlbuterolAsthmaSkin TestsEosinophil cationic proteinCumulative dosebusiness.industryReceptors Interleukin-2General MedicineBlood Proteinsrespiratory systemEosinophilAdrenergic beta-AgonistsEosinophil Granule ProteinsImmunoglobulin EMiddle Agedmedicine.diseaseBlood proteinsAsthmarespiratory tract diseasesBronchodilator AgentsEndocrinologymedicine.anatomical_structureImmunologySalbutamolFemalebusinessmedicine.drugInternational archives of allergy and immunology
researchProduct

Investigation into the role of phosphodiesterase IV in bronchorelaxation, including studies with human bronchus.

1993

1. We have investigated the role of cyclic nucleotide phosphodiesterase IV (PDE IV) in the relaxation of human bronchus and guinea-pig trachea in vitro and in guinea-pigs in vivo. 2. Functional studies showed that the selective PDE IV inhibitors, rolipram and denbufylline, relaxed human and guinea-pig preparations in vitro. 3. Two clinically used xanthine non-selective PDE inhibitors, theophylline and pentoxifylline, were also effective in these preparations, but were much less potent than the selective agents used. 4. The rank order of potency for the four PDE inhibitors in both species was similar. 5. Biochemical studies indicated that PDE IV was the major PDE isoform present in the human…

AdultMalemedicine.medical_specialtyPhosphodiesterase InhibitorsGuinea PigsBiologyIn Vitro TechniquesPentoxifyllinechemistry.chemical_compoundTheophyllineIn vivoInternal medicinemedicineAnimalsHumansTheophyllineheterocyclic compoundsPentoxifyllineRolipramAgedPharmacologyCyclic nucleotide phosphodiesterasePhosphoric Diester HydrolasesIsoproterenolMiddle AgedXanthinemusculoskeletal systemAsthmaPyrrolidinonesBronchodilator AgentsCyclic Nucleotide Phosphodiesterases Type 4IsoenzymesBronchodilatationenzymes and coenzymes (carbohydrates)Disease Models AnimalEndocrinologychemistryEnzyme inhibitor3'5'-Cyclic-AMP PhosphodiesterasesXanthinesbiology.proteinFemalesense organsRoliprammedicine.drugcirculatory and respiratory physiologyResearch Article
researchProduct